GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study - Wikidata - wikimedia - TriplyDB

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

http://www.wikidata.org/entity/Q24647794

about

Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis Glatiramer acetate for multiple sclerosis Natalizumab for relapsing remitting multiple sclerosis Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations The role of MRI in the evaluation of secondary progressive multiple sclerosis.Use of natalizumab in multiple sclerosis: current perspectives.Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis.Natalizumab in Multiple Sclerosis: Long-Term Management.The use of natalizumab for multiple sclerosis Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.New approaches in the management of multiple sclerosis.Safety of monoclonal antibodies for the treatment of multiple sclerosis.Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring.Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.Interferon beta and glatiramer acetate therapy.Natalizumab therapy for multiple sclerosis New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come.Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis.Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life.Update on the treatment options for multiple sclerosis.Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update.Treating multiple sclerosis with monoclonal antibodies: a 2010 update.Clinical evaluation of natalizumab for formulary consideration.Principles of a new treatment algorithm in multiple sclerosis.What happens when natalizumab therapy is stopped?Treating multiple sclerosis with natalizumab.Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.Treatment update in multiple sclerosis.Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.Immunotherapy of multiple sclerosis: the state of the art.Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.Natalizumab in multiple sclerosis: discontinuation, progressive multifocal leukoencephalopathy and possible use in children.

P2860

Q24187126-3F307E19-6B6F-46DB-9435-884C6F8F92D2 Q24202108-37385EE0-CCC2-47FA-98BE-27AF59D22192 Q24235498-1CF3FFED-7562-41D3-9716-A3F9F9798449 Q24235861-5FF65D2F-D471-43F4-9110-10ABB1848C3C Q26776234-8B86D0A1-7C31-4C97-A201-BD329ECC9544 Q27009769-6CA96C63-3A1E-45F5-9BED-3B5C7AA578B6 Q31033345-28069FC1-8B4E-483C-A07A-277376664144 Q31114633-CA2A31D1-E799-4EC3-B769-8EA71EF6357E Q33562198-3F86FF22-0337-41BC-97CA-5CDC7D4A6EAD Q33573208-DF849391-1EB2-4CDB-BF14-32B6E806B39A Q33692589-4FBA30DB-A74A-48B7-8ED7-CA516E305B19 Q33754882-E6FF77AE-AAD6-4932-8C6A-548CC872D17A Q33879159-9157ECB1-F7CF-4833-B7DE-3C6CC74D3117 Q33965415-29992701-175A-4778-B6D2-9187CF2E46B7 Q34389528-8A8621CE-C1E0-44DD-ABAE-6D564A0185B8 Q34542922-E22694CC-43CE-4C42-A375-8BC4D3CCBCD0 Q35093103-CA4ECB54-88C6-4B7C-B399-1EAFC6286385 Q35205472-5A091770-CA7B-4677-9E53-F7AB0DBF5EE5 Q35276622-7448CAF2-4E99-4A25-8DA9-511ABB557EB4 Q36568660-3DEEF60F-7D84-4687-BB9E-924D4E5E294A Q36568666-864C3D12-8A49-4216-8018-A21362CA5C6A Q36748702-B88AD39D-E8DF-4F4D-8DF9-C51D5FA1991F Q36789883-27A4B054-945F-4D56-980F-8AD1160AAD6E Q36951371-E2C3CFC0-E160-4F58-A0EF-035D7194CB6C Q37696989-F444E691-6AE3-485A-BDD6-BD292CE1E8E8 Q37729045-8680F1A0-E082-4D76-A863-72FD16BCE5E4 Q37732340-88B95DB4-55C0-4568-886E-5BA62AB691B9 Q37737305-7A948ABF-04E6-441E-BCD1-F5447DFAFD68 Q37772171-D85696F8-BEE8-4978-8503-E392E52353B7 Q37849763-E57D9732-7EF5-47F0-9EDB-4A7981E8B08A Q37921761-B565536F-13D1-44E0-A7E9-8F17EF35F2E3 Q37957123-E684BBB8-8135-4A6E-9DB3-EE6993A2CBF7 Q37968620-43F9D1B5-6FFE-4D39-BEDE-E03E76862A65 Q37996859-1AC9F863-2267-4B8E-94A3-5ED6DC1507AC Q37997089-2A2A617E-9365-4D92-96AC-7ECF96EA5DEB Q38083041-C8F31A3C-E337-4570-9179-13ECAE0ECA75 Q38152977-52AC5508-81C7-448D-96FD-2B408EA14EF5 Q38167347-691530F4-6835-4197-9E68-32303DB7D262 Q38558344-006CA3C2-8190-42C8-AE24-3097354E5855 Q38619288-23E9DDE1-1036-4AD4-BA3E-58D7422F2E68

P2860

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

http://www.wikidata.org/entity/Q24647794

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

@ast

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

@en

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

@nl

type

label

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

@ast

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

@en

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

@nl

prefLabel

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

@ast

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

@en

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

@nl

P1433

Q24647794-844DE3B3-232B-4A9E-A756-3931F704DF56

P1476

Q24647794-768EFAB2-5EE1-4BB9-91AC-12F1D1838C38

P2093

Q24647794-36BC2C48-6F4A-4F2F-AC5B-86DA64F57CD1

Q24647794-3BB7EBB5-B28C-41AF-AEA0-89091CF1F4EF

Q24647794-534F9A9D-436C-48A1-B89C-2CD102965787

Q24647794-5FC70408-3855-479F-8C93-B8894247B7F8

Q24647794-8AFC1A12-2723-4F12-9578-8B60B82ECE23

Q24647794-9BA05566-4DB2-463C-888C-7543EA220201

Q24647794-A7C93420-9FA5-4420-952D-604A23B5070C

Q24647794-B0EA45E6-1BBE-46FD-833D-08AFF0D0B784

Q24647794-B56F9451-0537-4B9B-9F91-7392734FA2A8

Q24647794-D5F2EEB0-9AB8-46D4-B84C-C9418E8F2443

P2860

Q24647794-0067566A-1DF5-4F85-A55D-AC044C289AE2

Q24647794-0291EBDF-BBE8-49CC-9C20-FB94B3157067

Q24647794-05B9B9A2-EE4C-4F6E-BC48-21DB53D8453B

Q24647794-05CB4A03-B043-4D1A-BDE1-95DD220F84DE

Q24647794-1116C8BD-DDF9-4DF0-A1A0-6F2E73C1D3B8

Q24647794-29F81D37-37E1-4EE0-8DBB-32290C16C11A

Q24647794-62233DE0-2425-4B29-81AE-0B8D6DF13DC3

Q24647794-7099F5D7-BE05-45B9-B942-53000AF2200A

Q24647794-76545327-78E7-417B-BF54-889A349EBEBF

Q24647794-80226101-F88D-41EB-B8E8-92058D76DCF3

P304

Q24647794-F062211C-7619-4C9C-9CF2-D765E98A5A49

P31

Q24647794-2F3283EE-EA99-4991-87C9-43CA0A3277A4

P356

Q24647794-E2AB1CDF-0137-4F2B-BDD9-5ACBAB50B406

P407

Q24647794-C134DCF6-1250-4F29-BCD1-B99895DF77F2

P433

Q24647794-2BA2336F-A18A-4640-A72A-8A37277BE75A

P478

Q24647794-BEC786AA-955C-40C6-9E2B-9CEC2D5D7726

P577

Q24647794-BDAC4D1A-C880-42DE-9AE8-E459DB2AA91D

P5875

Q24647794-280EEE96-3AF4-4731-8423-58A4DA070506

P698

Q24647794-A6E2F31E-546F-425B-9E4E-6152D13DA252

P921

Q24647794-C2AF9C36-7495-4372-82C2-CF41D75688C2

P932

Q24647794-0CE4FCD6-AD10-4E99-B845-C8AB8DA58AFB

P356

01.WNL.0000343880.13764.69

P1433

P1476

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

@en

P2093

A Bar-Or

http://www.w3.org/2001/XMLSchema#string

A D Goodman

http://www.w3.org/2001/XMLSchema#string

A Miller

http://www.w3.org/2001/XMLSchema#string

A W Sandrock

http://www.w3.org/2001/XMLSchema#string

D H Miller

http://www.w3.org/2001/XMLSchema#string

F Lublin

http://www.w3.org/2001/XMLSchema#string

H Rossman

http://www.w3.org/2001/XMLSchema#string

K Schmierer

http://www.w3.org/2001/XMLSchema#string

M A Panzara

http://www.w3.org/2001/XMLSchema#string

M Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Defining the clinical course of multiple sclerosis: Results of an international survey

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.

The pathophysiologic role of alpha 4 integrins in vivo

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

P304

806-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/01.WNL.0000343880.13764.69

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24171766

http://www.w3.org/2001/XMLSchema#string

P698

19255407

http://www.w3.org/2001/XMLSchema#string

P921

P932

2821836

http://www.w3.org/2001/XMLSchema#string